KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $7.9 million.

  • Neogenomics' Capital Expenditures fell 3214.07% to $7.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $27.0 million, marking a year-over-year decrease of 3422.47%. This contributed to the annual value of $27.0 million for FY2025, which is 3422.47% down from last year.
  • Neogenomics' Capital Expenditures amounted to $7.9 million in Q4 2025, which was down 3214.07% from $8.3 million recorded in Q3 2025.
  • Over the past 5 years, Neogenomics' Capital Expenditures peaked at $21.3 million during Q2 2021, and registered a low of $4.3 million during Q3 2023.
  • Over the past 5 years, Neogenomics' median Capital Expenditures value was $8.3 million (recorded in 2022), while the average stood at $9.6 million.
  • As far as peak fluctuations go, Neogenomics' Capital Expenditures soared by 32473.14% in 2021, and later plummeted by 6217.57% in 2022.
  • Quarter analysis of 5 years shows Neogenomics' Capital Expenditures stood at $12.0 million in 2021, then tumbled by 62.18% to $4.5 million in 2022, then surged by 55.65% to $7.1 million in 2023, then soared by 64.36% to $11.6 million in 2024, then tumbled by 32.14% to $7.9 million in 2025.
  • Its Capital Expenditures was $7.9 million in Q4 2025, compared to $8.3 million in Q3 2025 and $6.3 million in Q2 2025.